Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of JLP-2002 (Vibegron) in Healthy Volunteers
NCT04914221Phase 1Completed
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
- Start
- Mar 2021
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vibegron in overactive bladder (OAB) (3 arms), sponsored by Jeil Pharmaceutical Co., Ltd. Primary endpoints: Area Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration at 192 hours and Maximum Plasma Concentration at 192 hours. Started Mar 2021; status: completed.
02
Drugs
vibegron
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT04914221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04914221.